ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
COVID vaccines

COVID nasal spray vaccine set to enter clinical trial in Japan

Shionogi's inoculation method to help emerging nations lacking medical staff

OSAKA -- Shionogi will start clinical trials for a COVID-19 nasal spray vaccine in fiscal 2022, the Japanese pharmaceutical company announced Tuesday, paving the way for an inoculation method that would benefit countries lacking medical staff.

Shionogi has a licensing agreement with HanaVax to develop a nasal spray vaccine using the venture's proprietary drug delivery system. The technology uses a polysaccharide substance to deliver the vaccine through the nose, inducing immunity in the respiratory system.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more